{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:24:38Z","timestamp":1785864278037,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bmcl.2026.130717","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:40:36Z","timestamp":1782776436000},"page":"130717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells"],"prefix":"10.1016","volume":"140","author":[{"given":"Somaya A.","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustafa T.","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130717_bb0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2026.130717_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3103\/S0027131424700081","article-title":"High throughput screening in drug discovery: problems and solutions","volume":"79","author":"Hushpulian","year":"2024","journal-title":"Mosc Univ Chem Bull"},{"key":"10.1016\/j.bmcl.2026.130717_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130310","article-title":"CD28 and ICOS in immune regulation: structural insights and therapeutic targeting","volume":"127","author":"Upadhyay","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130717_bb0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bmcl.2026.130717_bb0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2026.130717_bb0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody Vibostolimab as monotherapy or with Pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400545","article-title":"Discovery of ICOS-targeted small molecules using affinity selection mass spectrometry screening","volume":"19","author":"Zhang","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2026.130717_bb0040","doi-asserted-by":"crossref","first-page":"25112","DOI":"10.1021\/acs.jmedchem.5c02136","article-title":"Discovery of CD28-targeted small molecule inhibitors of T cell co-stimulation using affinity selection-mass spectrometry and ex vivo validation","volume":"68","author":"Upadhyay","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130717_bb0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrd.2016.29","article-title":"Small molecules, big targets: drug discovery faces the protein\u2013protein interaction challenge","volume":"15","author":"Scott","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2026.130717_bb0050","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/1568026618666180531092503","article-title":"Toward Small-Molecule Inhibition of Protein\u2013Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions","volume":"18","author":"Bojadzic","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmcl.2026.130717_bb0055","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2174\/138620709789824736","article-title":"Protein-protein interaction inhibition (2P2I): fewer and fewer undruggable targets","volume":"12","author":"Betzi","year":"2009","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.bmcl.2026.130717_bb0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41580-021-00407-0","article-title":"A guide to machine learning for biologists","volume":"23","author":"Greener","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0065","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nbt.4233","article-title":"Deep learning in biomedicine","volume":"36","author":"Wainberg","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0070","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cell.2020.01.021","article-title":"A deep learning approach to antibiotic discovery","volume":"180","author":"Stokes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2026.130717_bb0075","doi-asserted-by":"crossref","first-page":"28321","DOI":"10.1038\/s41598-024-79799-w","article-title":"Deep learning pipeline for accelerating virtual screening in drug discovery","volume":"14","author":"Noor","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2026.130717_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202300207","article-title":"HIt discovery using docking ENriched by GEnerative modeling (HIDDEN GEM): a novel computational workflow for accelerated virtual screening of ultra-large chemical libraries","volume":"43","author":"Popov","year":"2024","journal-title":"Mol Inform"},{"key":"10.1016\/j.bmcl.2026.130717_bb0085","doi-asserted-by":"crossref","first-page":"18013","DOI":"10.1074\/jbc.M111.221028","article-title":"Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3\/LIR-5\/CD85k)","volume":"286","author":"Cheng","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130717_bb0090","article-title":"Leukocyte immunoglobulin-like receptor B4: a keystone in immune modulation and therapeutic target in cancer and beyond","volume":"3","author":"Lu","year":"2024","journal-title":"Cancer Innov"},{"key":"10.1016\/j.bmcl.2026.130717_bb0095","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130717_bb0100","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.4049\/jimmunol.1100274","article-title":"Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer","volume":"186","author":"Krempski","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5114\/ceji.2023.125238","article-title":"Molecular regulatory mechanism of LILRB4 in the immune response","volume":"48","author":"Liu","year":"2023","journal-title":"Cent Eur J Immunol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0110","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.4049\/jimmunol.178.11.7432","article-title":"Soluble Ig-like transcript 3 inhibits tumor alloreactivity and generates CD8+ suppressor T cells","volume":"178","author":"Suciu-Foca","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0115","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1172\/JCI97570","article-title":"Blocking immunoinhibitory receptor LILRB4 on antigen-presenting cells enhances antitumor immunity","volume":"128","author":"Chen","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmcl.2026.130717_bb0120","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41556-019-0298-1","article-title":"Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response","volume":"21","author":"Salvagno","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/BS9.0000000000000109","article-title":"LILRB4, an immune checkpoint on myeloid cells","volume":"4","author":"Yang","year":"2022","journal-title":"Blood Sci"},{"key":"10.1016\/j.bmcl.2026.130717_bb0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jlb.66.3.375","article-title":"A novel family of inhibitory receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells","volume":"66","author":"Colonna","year":"1999","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.0001-2815.2004.00290.x","article-title":"The LILR family: modulators of innate and adaptive immune pathways in health and disease","volume":"64","author":"Brown","year":"2004","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.bmcl.2026.130717_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1282874","article-title":"Human leukocyte immunoglobulin-like receptors in health and disease","volume":"14","author":"Redondo-Garc\u00eda","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40364-024-00705-7","article-title":"The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications","volume":"12","author":"Hodges","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.bmcl.2026.130717_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118253","article-title":"The immune checkpoint LILRB4 promotes immune evasion and is correlated with disease progression and secondary malignancies in chronic lymphocytic leukemia","volume":"189","author":"Sordo-Bahamonde","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2026.130717_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiaf052","article-title":"Presence of LILRB4 SNP rs1048801 modulates acute myeloid leukemia progression and inhibits CD4+ T cells proliferation","volume":"117","author":"Zhou","year":"2025","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100126","article-title":"A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia","volume":"2","author":"Aribi","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.bmcl.2026.130717_bb0165","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/intimm\/dxab028","article-title":"Blockade of checkpoint ILT3\/LILRB4\/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB\/Yaa mice","volume":"33","author":"Su","year":"2021","journal-title":"Int Immunol"},{"key":"10.1016\/j.bmcl.2026.130717_bb0170","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1158\/1535-7163.MCT-20-0407","article-title":"LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia","volume":"19","author":"Anami","year":"2020","journal-title":"Mol Cancer Ther"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:21:21Z","timestamp":1785860481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26001848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S0960894X26001848"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130717","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130717"}}